Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 35.07M shares outstanding
USFennec Pharmaceuticals Inc. operates as a biopharmaceutical firm.
Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy.
The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014.
Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Chris A. Rallis
Director(2)(3)(4)
Dr. Khalid Islam
Chairman of Board, Director(2)
Dr. Marco Brughera
Director(2)(3)(4)
Jeff Hackman
Chief Executive Officer, Director
Employees
32
Country
US
Sector
Healthcare
Website
fennecpharma.com
Loading congressional disclosures…
based on 35.07M shares outstanding
US30d Avg
135.60K
60d Avg
195.69K
90d Avg
189.78K
